HpBARI administered at day 0 was able to suppress BAL and lung eosinophilia, and ILC2 and CD4+ T cell IL-13 production, although in the case of ILC2 IL-13 production this did not reach statistical significance (Figure 4A–D). Here, IL13 is linked to Increased total eosinophil count.